CESK1 Antibody (OTI2A5) [Janelia Fluor® 635]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-72413JF635
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Immunocytochemistry/ Immunofluorescence, Western Blot
Label
Janelia Fluor 635
Antibody Source
Monoclonal Mouse IgG1 Clone # OTI2A5
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Full length human recombinant protein of human CCT8L2(NP_055221) produced in E.coli.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Applications for CESK1 Antibody (OTI2A5) [Janelia Fluor® 635]
Application
Recommended Usage
Immunocytochemistry/ Immunofluorescence
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CESK1
Alternate Names
CESK1MGC118839, chaperonin containing TCP1, subunit 8 (theta)-like 2, MGC118840, putative T-complex protein 1 subunit theta-like 2, T-complex protein 1
Gene Symbol
CCT8L2
Additional CESK1 Products
Product Documents for CESK1 Antibody (OTI2A5) [Janelia Fluor® 635]
Product Specific Notices for CESK1 Antibody (OTI2A5) [Janelia Fluor® 635]
Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...